Geeson Cathy, Wei Li, Franklin Bryony Dean
Luton and Dunstable University Hospital, Luton, UK.
UCL School of Pharmacy, London, UK.
Int J Pharm Pract. 2020 Dec;28(6):643-651. doi: 10.1111/ijpp.12602. Epub 2020 Feb 12.
Hospital pharmacy is undergoing a period of rapid change, with pharmacists needing to focus where they add most value. Our aim was to identify where pharmacists have potential for greatest impact by analysing data on clinically relevant medication-related problems (MRPs).
We included consecutive admissions from adult medical wards at two UK hospitals between April and November 2016. MRPs were identified by pharmacists at the study sites as part of their routine daily patient assessments, validated and assessed for preventability and severity. Descriptive analyses were performed on clinically relevant (moderate or severe preventable) MRPs to establish the stage of inpatient stay where identified and their types/categories (overall and by stage of inpatient stay).
Among 1503 eligible admissions, 2614 validated MRPs were identified, of which 1153 were moderate or severe, and preventable. Over 70% of these clinically relevant MRPs were identified during/before the first ward-based pharmacy review of patients. The most frequent MRP subcategory was 'indication not treated/missing therapy', accounting for 46% of clinically relevant MRPs. Dose selection issues were the next most common, accounting for 24%. The subcategory 'indication not treated/missing therapy' was identified more frequently at admission and discharge (53% and 45% of MRPs, respectively) compared with during the inpatient stay (14%), P < 0.001.
This research suggests patients are at greatest need of pharmacist input in terms of identification/resolution of clinically relevant MRPs during early stages of inpatient stay; however, clinically relevant MRPs continue to occur throughout their stay, suggesting need for ongoing pharmacy review.
医院药房正经历快速变革时期,药剂师需要专注于能产生最大价值的领域。我们的目标是通过分析与临床相关的用药相关问题(MRP)数据,确定药剂师在哪些方面可能产生最大影响。
我们纳入了2016年4月至11月期间英国两家医院成人内科病房的连续入院患者。研究地点的药剂师在日常患者评估中识别MRP,并对其可预防性和严重性进行验证和评估。对与临床相关的(中度或重度可预防的)MRP进行描述性分析,以确定其在住院期间被识别的阶段及其类型/类别(总体以及按住院阶段)。
在1503例符合条件的入院患者中,共识别出2614个经过验证的MRP,其中1153个为中度或重度且可预防。超过70%的这些与临床相关的MRP是在对患者进行首次病房药房评估期间/之前识别出来的。最常见的MRP子类别是“未治疗的适应症/遗漏治疗”,占与临床相关的MRP的46%。剂量选择问题是第二常见的,占24%。与住院期间(14%)相比,“未治疗的适应症/遗漏治疗”子类别在入院时和出院时被识别的频率更高(分别占MRP的53%和45%),P<0.001。
这项研究表明,就识别/解决住院早期与临床相关的MRP而言,患者最需要药剂师的参与;然而,与临床相关的MRP在整个住院期间持续出现,这表明需要持续进行药房评估。